MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Aptevo Therapeutics EBITDA per Share 2011-2026 | APVO
Annual EBITDA per Share Aptevo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82.6 | -31.6 K | -3.77 K | -5.44 | -4.32 | -8.07 | -13.8 | -30.7 | -33.3 | -36.4 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.32 | -31.6 K | -3.56 K |
Quarterly EBITDA per Share Aptevo Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -4.4 | - | - | - | -371 | - | - | - | -47.5 | - | -1.38 | -1.4 | -1.09 | - | -0.79 | -1.13 | -1.49 | - | -1.6 | -1.87 | -2.19 | - | -3.02 | -3.64 | -6.9 | - | -0.46 | -0.5 | -0.59 | - | -0.34 | -0.61 | -0.54 | -0.72 | -4.33 | -0.55 | -0.6 | - | -0.55 | -0.88 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.34 | -371 | -17 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
-8.81 | $ 8.79 | 0.8 % | $ 86.9 M |  USA |
 |
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-1.68 | $ 3.6 | -1.64 % | $ 8.66 B |  Australia |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-0.6 | $ 3.23 | 3.7 % | $ 275 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.05 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-0.77 | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-1.97 | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioNTech SE
BNTX
|
62.6 | $ 97.22 | 0.54 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
1.11 | $ 4.64 | 3.45 % | $ 754 M | Britain |
 |
Cabaletta Bio
CABA
|
-1.7 | $ 3.21 | 0.16 % | $ 323 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
3.68 | $ 21.3 | -0.3 % | $ 996 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-1.42 | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-6.85 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
-0.4 | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
CNS Pharmaceuticals
CNSP
|
-36 | $ 2.46 | -2.19 % | $ 1.09 M | USA |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
0.1 | $ 1.51 | 2.59 % | $ 388 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.15 | 7.87 % | $ 5.19 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
-0.66 | $ 4.2 | 0.24 % | $ 449 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 25.08 | 3.96 % | $ 3.19 B | USA |
 |
Chimerix
CMRX
|
-1.05 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-2.21 | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Evogene Ltd.
EVGN
|
-0.77 | $ 0.82 | -0.07 % | $ 27.9 M | Israel |
 |
Celldex Therapeutics
CLDX
|
-4.28 | $ 32.73 | 0.43 % | $ 2.17 B | USA |
|
Forte Biosciences
FBRX
|
-5.45 | $ 32.72 | 6.91 % | $ 424 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-0.99 | $ 1.49 | 1.27 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-27.7 | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
0.24 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
0.74 | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |